Abbott Laboratories: A Strong Buy Amidst Undervaluation and Robust Fundamentals
Finance

Abbott Laboratories: A Strong Buy Amidst Undervaluation and Robust Fundamentals

authorBy Fareed Zakaria
DateJun 12, 2026
Read time2 min

In the healthcare sector, particularly within medical devices, certain companies often demonstrate resilience against broader economic fluctuations. Abbott Laboratories stands out as such an entity, presenting a strong investment opportunity.

Abbott Laboratories is currently considered a strong buy, primarily due to its structural undervaluation and robust underlying business. Despite recent dips in its stock price, the company maintains solid fundamentals. When compared to its competitors, Abbott trades at a significant discount, specifically a 17.1% lower price-to-earnings ratio and a 35.1% lower sales multiple. Furthermore, discounted cash flow analyses indicate a potential upside of 21.8% to 39.4% to its fair value. This suggests that the market has yet to fully recognize Abbott's inherent worth.

The company's future growth trajectory is supported by several key initiatives. The acquisition of Exact Sciences is expected to bolster its market position, while ongoing advancements in diagnostics and the global expansion of its continuous glucose monitoring (CGM) systems are set to drive revenue. In fact, Abbott has already raised its sales and earnings per share guidance for fiscal year 2026, underscoring confidence in these growth drivers. The prevailing analyst consensus is highly bullish, with an average one-year price target of $116.32, reinforcing the expectation of a significant re-rating for Abbott's stock. This positive outlook, combined with its current market position, makes Abbott Laboratories an attractive prospect for investors seeking value and growth in the medical device industry.

Abbott Laboratories embodies the principle that foundational strength and strategic foresight are key to enduring success. Its commitment to innovation, measured through acquisitions and market expansion, positions it for sustained growth. For investors, this represents not just a chance for financial gain, but an opportunity to support a company that contributes significantly to global health advancements, providing essential medical devices and diagnostic solutions that improve lives worldwide. Investing in such enterprises offers both prosperity and purpose.

More Articles
Finance
Stantec: An Undervalued Opportunity in Engineering and Construction
Stantec, a prominent engineering and construction firm, has consistently delivered strong financial performance. With a diversified global operational footprint, the company effectively mitigates risks. It stands as a leader in wastewater management, a sector poised for significant long-term expansion. The recent decline in its stock price, observed since October 2025, now presents an attractive investment prospect.
By Nouriel RoubiniJun 12, 2026
Finance
Gabelli Dividend Growth Fund: Navigating Q1 2026 Market Dynamics
The Gabelli Dividend Growth Fund saw a 2.4% rise in Q1 2026, outperforming the S&P 500's 4.3% decline, and slightly surpassed the Russell 1000 Value Index's 2.1% gain. Strategic adjustments included reducing exposure to Newmont Corp. and initiating new positions in tech and healthcare firms like Comcast, Airbnb, Alibaba, HubSpot, and Moderna, with an emphasis on AI integration and emerging therapeutic areas like cancer vaccines. Merck's robust pipeline also contributes to the fund's growth strategy.
By Fareed ZakariaJun 12, 2026
Finance
Marvell's Trillion-Dollar Ambition: A Reality Check
Marvell Technology has garnered significant attention following Nvidia CEO's forecast of its potential trillion-dollar valuation. However, a deeper analysis reveals that the current stock price already incorporates aggressive growth expectations. While Marvell boasts strong fundamentals in optical DSPs and XPUs for AI data centers, fueled by its Nvidia collaboration, achieving such a valuation by 2030 would necessitate exceptional revenue and margin expansion. This article suggests a cautious 'Hold' rating, advocating for selling put options to generate high-probability returns with reduced valuation risk.
By Mariana MazzucatoJun 12, 2026
Finance
LyondellBasell: Navigating the Chemical Industry's Cyclical Downturn
LyondellBasell (LYB) is currently facing a challenging period, but strategic operational streamlining and financial adjustments suggest potential for recovery. Despite a cautious "Buy" rating at $65, the company grapples with subdued earnings and an elevated net debt-to-EBITDA ratio. The key to its future lies in the resurgence of polyethylene/polypropylene margins, which are currently constrained by China's expanding production and export activities. However, the company benefits from a competitive advantage in U.S. feedstock. The valuation appears appealing if earnings stabilize at $6-7 per share, with a target of $78 and a stronger safety net below $55-60.
By Morgan HouselJun 12, 2026
Finance
Lennar's Housing Market Challenges: A 'Sell' Rating Maintained Amidst Slow Recovery
Lennar faces ongoing headwinds in the housing sector, with persistent weak demand, affordability issues, and high interest rates impeding recovery. The company's Q2 earnings dropped by 30% year-over-year, gross margins narrowed to 15.6%, and increased incentives were necessary to maintain sales volumes. Full-year guidance reflects continued market softness, with home deliveries projected lower than previously expected. Despite a strong financial position and share buybacks, the stock's current valuation seems to anticipate an improbable swift rebound.
By Lisa JingJun 12, 2026